Latest Breaking News On - Christopher graybill - Page 1 : comparemela.com
Dekker was most recently vice president of finance at Louisville-based biotechnology company GlobeImmune Inc., where he held finance roles for more than 15 years. He replaces Brian Selby, who left after 14 years at Arca.
Graybill was most recently at Lakewood-based Terumo BCT, the blood and cell-technology arm of Tokyo-based medical-device maker Terumo Corp., where he held global clinical affairs and research for just more than six years. He also had stints at DaVita Inc. (NYSE: DVA), PRA Health Sciences Inc. (Nasdaq: PRAH) and Gilead Sciences Inc. (Nasdaq: GILD).
Arca, which is based in Westminster, is focused on cardiovascular treatments. Its lead drug candidate AB201 was first brought into clinical trials as an anti-blood clot agent for cardiac patients, but the company pivoted to researching AB201 as a possible treatment for severe bouts of COVID-19.
Tokyo
Japan
Brian-selby
Jeff-dekker
Christopher-graybill
Terumo-corp
Davita-inc
Globeimmune-inc
Bizwest-media
Arca-biopharma-inc
Gilead-sciences-inc
Health-sciences-inc
Christopher Graybill Joins ARCA as Vice President, Clinical Development
May 05, 2021 16:05 ET | Source: ARCA biopharma, Inc. ARCA biopharma, Inc. Westminster, Colorado, UNITED STATES
WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Christopher Graybill, Ph.D., has joined ARCA as Vice President, Clinical Development.
Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We are delighted to welcome Christopher to ARCA as Vice President of Clinical Development. His over 14 years of experience in the biotechnology and medical device industries, supporting global clinical strategy, clinical trial planning and conduct, and other aspects of product development including in the cardiovascular space, will be a
Derek-cole
Christopher-graybill
Michael-bristow
Gilead-sciences
Myogen-inc
Davita-clinical-research
Susquehanna-university
Nasdaq
Exchange-commission
University-of-massachusetts
Company-on-linkedin
School-of-biomedical-sciences